Cette désignation atteste de la gravité de la maladie et du potentiel de l'énéboparatide pour faire face au besoin urgent de nouvelles options thérapeutiques répondant aux objectifs clés du traitement de l'hypoparathyroïdie Cette désignation atteste de la gravité de la maladie et du potentiel de l'énéboparatide pour faire face au besoin urgent de nouvelles options thérapeutiques répondant aux objectifs clés du traitement de l'hypoparathyroïdie The post Amolyt Pharma obtient la désignation Fast Track de la FDA pour l’énéboparatide dans le traitement de l’hypoparathyroïdie appeared first on Bio ..read more

Longeveron to report Q1 2024 financial results on May 14, 2024. The post Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 appeared first on Bio Tech Winners ..read more

RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2024, before the financial markets open on Thursday, May 9, 2024. The post Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024 appeared first on Bio Tech Winners ..read more

SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, is pleased to announce the appointment of Matt Valentino as Chief People Officer. The post Shape Therapeutics Announces Appointment of Matt Valentino as Chief People Officer appeared first on Bio Tech Winners ..read more

Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial The post Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial appeared first on Bio Tech Winners ..read more

Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent by the European Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1 (New York esophageal squamous cell carcinoma 1), a well-recognized and validated cancer-testis antigen, which is expressed in multiple tumor types.  The post Medigene AG Expands Patent Portfolio with European Patent Grant for i ..read more

BERN, Switzerland and BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Ikerian AG and its subsidiary, RetinAI U.S. Inc., a leading developer of software solutions for medical image and data management, and artificial intelligence (AI) in healthcare, announced today the successful close of its USD 6.18M (CHF 5.65M) Series A Extension financing, with new and existing investors. The post Ikerian AG, Parent Company of RetinAI U.S. Inc. Announces Final Close of USD 6.18M (CHF 5.65M) Series A Extension Financing appeared first on Bio Tech Winners ..read more

Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presented superior T cell receptor engineered T (TCR-T) cell functionality upon combination of optimal affinity 3S (sensitive, specific and safe) TCRs with the PD1-41BB costimulatory switch protein (CSP) at the 7th International Neoantigen Summit held in Amsterdam, Netherlands from April 29 - May 1, 2024. The post Medigene Presents Superior TCR-T Cell Functionality by Inclu ..read more

May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2024 financial results and provide a business update. The post argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024 appeared first on Bio Tech Winners ..read more

   The post CARBIOS und Hündgen schließen Liefervereinbarung für die weltweit erste PET-Biorecycling-Anlage appeared first on Bio Tech Winners ..read more